Dual release behavior of atorvastatin and alpha-lipoic acid from PLGA microspheres for the combination therapy in peripheral nerve injury


EROĞLU H., Haidar M. K., NEMUTLU E., ÖZTÜRK Ş., BAYRAM C., ULUBAYRAM K., ...Daha Fazla

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.39, ss.455-466, 2017 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.jddst.2017.04.028
  • Dergi Adı: JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.455-466
  • Anahtar Kelimeler: Combination therapy, Atorvastatin calcium, Alpha-lipoic acid, Microsphere, Peripheral nerve injury, SPINAL-CORD-INJURY, ANTI-INHIBITORY MOLECULES, CEREBRAL-ISCHEMIA, DRUG-DELIVERY, ANTIOXIDANT, SURVIVAL, STATINS, DEGRADATION, ACTIVATION, REDUCTASE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

The major focus of this study was to prepare poly(lactic-co-glycolic) acid (PLGA) microspheres containing atorvastatin calcium (ATR) in combination with alpha-lipoic acid (ALA). PLGA microspheres will maintain dual-release for providing neuroprotective effects for peripheral nerve injury. For this purpose, micro spheres were prepared by spray dryer with different drug:polymer ratios. Microsphere formulations were evaluated for particle size distribution, preparation and encapsulation efficiency, surface morphology, in-vitro release and dose dependent cytotoxicity test with L-929 and B-35 cells. TGA, DSC and FTIR analysis were performed for the investigation of physicochemical properties of the PLGA microspheres. Encapsulation efficiencies were calculated as > 70% for ALA and > 62% for ATR. FTIR results indicated that there was no interaction between the polymer and the active ingredients. A novel analytical method has been developed and fully validated, which would allow for quantification of ATR and ALA simultaneously. Release profiles showed that ALA is released within the first 17 h and ATR release lasted for 17 days. Finally, results showed that there was no any toxicity associated with ALA and ATR containing PLGA formulations on both B-35 and L-929 cells. It was concluded that PLGA formulations with dual effects are promising systems for the treatment of peripheral nerve injury. (C) 2017 Elsevier B.V. All rights reserved.